5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005158:Facial Paralysis / Q000139:chemically induced; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014226:Triazenes